FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056545314> ?p ?o ?g. }

• W2056545314 endingPage "181" @default.
• W2056545314 startingPage "177" @default.
• W2056545314 abstract "To estimate the response rate and therapy related toxicities of the anti-CD20 monoclonal antibody rituximab when combined with chemotherapy including ifosfamide, carboplatin, and etoposide (ICE) in patients with relapsed and refractory B-cell non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia (B-ALL).Patients received rituximab and ICE for 1-3 cycles, depending upon response. Rituximab (375 mg/m(2)) was given on day 1 and 3 of each cycle (day 1 only for cycle 3), with ifosfamide (3,000 mg/m(2)) and etoposide (100 mg/m(2)) given on days 3, 4, and 5 and carboplatin (635 mg/m(2)) given on day 3 only.Twenty-one patients were enrolled, of whom 20 were eligible and evaluable. Although hematologic toxicities were common, only one patient was removed from study due to prolonged myelosuppression. Toxicities related to infusions of rituximab were frequent but manageable. Of the six eligible patients with diffuse large B-cell lymphoma, three achieved complete remission (CR), one had stable disease (SD), and two had progressive disease (PD). Of the 14 eligible patients with Burkitt lymphoma and B-ALL, there were four complete responses (CR), five partial responses (PR), one SD, and four with PD. Thus, the CR/PR rate for the entire group was 12/20 (60%). Following completion of protocol therapy six patients were able to proceed to consolidation with high-dose therapy and stem cell rescue.The combination of rituximab and ICE chemotherapy was associated with an encouraging objective response (OR) rate and an acceptable toxicity profile." @default.
• W2056545314 created "2016-06-24" @default.
• W2056545314 creator A5001142989 @default.
• W2056545314 creator A5001697191 @default.
• W2056545314 creator A5009549092 @default.
• W2056545314 creator A5009716898 @default.
• W2056545314 creator A5023092047 @default.
• W2056545314 creator A5027364145 @default.
• W2056545314 creator A5048012532 @default.
• W2056545314 creator A5048057394 @default.
• W2056545314 creator A5060291120 @default.
• W2056545314 creator A5069603123 @default.
• W2056545314 creator A5073848195 @default.
• W2056545314 date "2009-02-01" @default.
• W2056545314 modified "2023-09-26" @default.
• W2056545314 title "A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: A report from the Children's Oncology Group" @default.
• W2056545314 cites W15360658 @default.
• W2056545314 cites W1685882185 @default.
• W2056545314 cites W1912693401 @default.
• W2056545314 cites W1950269930 @default.
• W2056545314 cites W1972286219 @default.
• W2056545314 cites W1974824259 @default.
• W2056545314 cites W1975280591 @default.
• W2056545314 cites W1984151990 @default.
• W2056545314 cites W2000871066 @default.
• W2056545314 cites W2011539491 @default.
• W2056545314 cites W2025404731 @default.
• W2056545314 cites W2045940197 @default.
• W2056545314 cites W2049882831 @default.
• W2056545314 cites W2131904409 @default.
• W2056545314 cites W2132714764 @default.
• W2056545314 cites W2160305510 @default.
• W2056545314 cites W2167571754 @default.
• W2056545314 cites W2170558243 @default.
• W2056545314 cites W2263029236 @default.
• W2056545314 cites W2316588149 @default.
• W2056545314 cites W2418093107 @default.
• W2056545314 doi "https://doi.org/10.1002/pbc.21753" @default.
• W2056545314 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2728935" @default.
• W2056545314 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18816698" @default.
• W2056545314 hasPublicationYear "2009" @default.
• W2056545314 type Work @default.
• W2056545314 sameAs 2056545314 @default.
• W2056545314 citedByCount "142" @default.
• W2056545314 countsByYear W20565453142012 @default.
• W2056545314 countsByYear W20565453142013 @default.
• W2056545314 countsByYear W20565453142014 @default.
• W2056545314 countsByYear W20565453142015 @default.
• W2056545314 countsByYear W20565453142016 @default.
• W2056545314 countsByYear W20565453142017 @default.
• W2056545314 countsByYear W20565453142018 @default.
• W2056545314 countsByYear W20565453142019 @default.
• W2056545314 countsByYear W20565453142020 @default.
• W2056545314 countsByYear W20565453142021 @default.
• W2056545314 countsByYear W20565453142022 @default.
• W2056545314 countsByYear W20565453142023 @default.
• W2056545314 crossrefType "journal-article" @default.
• W2056545314 hasAuthorship W2056545314A5001142989 @default.
• W2056545314 hasAuthorship W2056545314A5001697191 @default.
• W2056545314 hasAuthorship W2056545314A5009549092 @default.
• W2056545314 hasAuthorship W2056545314A5009716898 @default.
• W2056545314 hasAuthorship W2056545314A5023092047 @default.
• W2056545314 hasAuthorship W2056545314A5027364145 @default.
• W2056545314 hasAuthorship W2056545314A5048012532 @default.
• W2056545314 hasAuthorship W2056545314A5048057394 @default.
• W2056545314 hasAuthorship W2056545314A5060291120 @default.
• W2056545314 hasAuthorship W2056545314A5069603123 @default.
• W2056545314 hasAuthorship W2056545314A5073848195 @default.
• W2056545314 hasBestOaLocation W20565453142 @default.
• W2056545314 hasConcept C126322002 @default.
• W2056545314 hasConcept C141071460 @default.
• W2056545314 hasConcept C143998085 @default.
• W2056545314 hasConcept C18031839 @default.
• W2056545314 hasConcept C2776694085 @default.
• W2056545314 hasConcept C2777506904 @default.
• W2056545314 hasConcept C2778119113 @default.
• W2056545314 hasConcept C2778239845 @default.
• W2056545314 hasConcept C2778822529 @default.
• W2056545314 hasConcept C2779338263 @default.
• W2056545314 hasConcept C2780653079 @default.
• W2056545314 hasConcept C2781451048 @default.
• W2056545314 hasConcept C71924100 @default.
• W2056545314 hasConcept C90924648 @default.
• W2056545314 hasConceptScore W2056545314C126322002 @default.
• W2056545314 hasConceptScore W2056545314C141071460 @default.
• W2056545314 hasConceptScore W2056545314C143998085 @default.
• W2056545314 hasConceptScore W2056545314C18031839 @default.
• W2056545314 hasConceptScore W2056545314C2776694085 @default.
• W2056545314 hasConceptScore W2056545314C2777506904 @default.
• W2056545314 hasConceptScore W2056545314C2778119113 @default.
• W2056545314 hasConceptScore W2056545314C2778239845 @default.
• W2056545314 hasConceptScore W2056545314C2778822529 @default.
• W2056545314 hasConceptScore W2056545314C2779338263 @default.
• W2056545314 hasConceptScore W2056545314C2780653079 @default.
• W2056545314 hasConceptScore W2056545314C2781451048 @default.
• W2056545314 hasConceptScore W2056545314C71924100 @default.
• W2056545314 hasConceptScore W2056545314C90924648 @default.
• W2056545314 hasIssue "2" @default.

• next